BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED.

AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from study AB12003.

Upsher-Smith Laboratories, LLC announced that it has entered into a definitive agreement under which New Jersey-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines, Inc. have acquired Zembrace® SymTouch® 3 mg and Tosymra® 10 mg.

Aptose Biosciences Inc. announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC notifying the Company that it meets compliance with the Nasdaq’s minimum bid price requirement.

Nkarta, Inc. (Nasdaq: NKTX) today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX101, its allogeneic, off-the-shelf CAR NK cell therapy candidate engineered to target NKG2D ligands on cancer cells.

Acadia Pharmaceuticals Inc. announced that on June 13, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 153,615 shares of common stock and 56,399 restricted stock units to 28 new employees under Acadia’s 2023 Inducement Plan.

Politan Capital Management, a 9% shareholder of Masimo Corporation, commented on the outcome of the Company’s Annual Meeting of Stockholders.

Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide 1 (GLP-1)/glucagon (GCG) receptor agonist, retatrutide.

Blue Earth Diagnostics today announced results of a post-hoc analysis assessing the impact of urinary activity on the interpretation of POSLUMA® (flotufolastat F 18) injection (formerly known as 18F-rhPSMA-7.3) PET/CT in prostate cancer.

DiaMedica Therapeutics Inc. today announced the closing of its previously announced $37.5 million private placement to accredited investors.